Analyst Price Targets — PRME
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 29, 2026 10:02 am | — | New Street | $8.00 | $3.43 | TheFly | Prime Medicine upgraded to Buy from Neutral at H.C. Wainwright |
| June 22, 2026 8:16 am | — | Goldman Sachs | $6.00 | $3.23 | StreetInsider | Prime Medicine (PRME) Reiterated at Market Outperform by Citizens as Trial Announced |
| May 7, 2024 8:07 am | Maury Raycroft | Jefferies | $15.00 | $5.40 | TheFly | Prime Medicine assumed with a Buy at Jefferies |
| April 2, 2024 4:15 pm | David Nierengarten | Wedbush | $12.00 | $6.32 | TheFly | Prime Medicine initiated with a Buy at Wedbush |
| October 9, 2023 2:19 pm | Kostas Biliouris | BMO Capital | $19.00 | $8.75 | Benzinga | Preclinical-Phase Firm Prime Medicine's Gene Editing Platform Has Potential: Analyst |
| November 14, 2022 6:19 am | — | Morgan Stanley | $23.00 | $21.12 | Benzinga | Morgan Stanley Initiates Coverage On Prime Medicine with Equal-Weight Rating, Announces Price Target of $23 |
Latest News for PRME
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in…
Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dispute with Beam Therapeutics Inc. (NASDAQ:BEAM).
-- Arbitration tribunal declared that PM647 is within Prime Medicine's “Field”, confirming Prime Medicine's right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary damages to Beam Therapeutics -- -- Prime Medicine plans to submit an IND and/or CTA filing for PM647 in Q3 2026, initial clinical data expected in 2027 -- CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Prime Medicine,…
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359's potential to address unmet need in p47 phox -deficient CGD -- -- Designation enables early and intensive FDA engagement, and provides eligibility for rolling and priority Biologics License Application review -- -- PM359 now holds RMAT, Fast Track, Orphan…
-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe --
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRME.
U.S. House Trading
No House trades found for PRME.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.